NC Biopharmaceutical Company, Chelsea Therapeutics Fills Key Positions

Strong management team seeks to find cures for rheumatoid arthritis, psoriasis, cancer and other immunological disorders.

Charlotte, NC (PRWEB) October 2, 2004 -- Chelsea Therapeutics, Inc. today announced the hiring of their core team of senior executives:

L. Arthur Hewitt, Ph.D. - Vice President of Drug Development
Dr. Hewitt has over 25 years of pharmaceutical industry experience working for Abbott Laboratories, Parke-Davis, Janssen Pharmaceuticals and Amgen. While at Amgen he was the Head of Clinical Research and Regulatory Affairs in Canada. During his years at Amgen, Dr. Hewitt oversaw the approval of Neupogen, Stemgen and Infergen. Dr. Hewitt obtained his Ph.D. in Pharmacology from the Medical School at the University of Montreal.

J. Nick Riehle, MBA - Vice President, Administration and CFO
Mr. Riehle has over 25 years of business and management experience with both large fortune 500 companies and start-up ventures. He has held senior positions at HAHT Commerce, Nortel Networks and IBM. In addition he has had significant success in venture financing and supporting rapid growth businesses. Mr. Riehle has a Bachelor of Commerce degree from McGill University, an MBA from York University and earned a Certified Management Accountant (CMA) designation from Ontario, Canada.

Michael J. Roberts, Ph.D. - Director, Business Development
Dr. Roberts joined Chelsea from Nektar Therapeutics where he was Director of Business Development for their Molecule Engineering technology. Prior to this he was Manager of Biopharmaceutical Research at Shearwater Corporation where he lead and was successful in the development of preclinical drug candidates from initial stages of research through Phase I clinical study. Dr. Roberts obtained his Ph.D. in Materials Science from the University of Alabama in Huntsville and B.S. in Chemical Engineering from Pennsylvania State University.

Cameron B. Szakacs, Ph.D. - Assoc. Director, Drug Development
Dr. Szakacs joined Chelsea Therapeutics from Nektar Therapeutics (formerly Shearwater Corporation), where he was responsible for running preclinical programs. Previously Dr. Szakacs oversaw clinical development programs for Endpoint Research (a Canadian Clinical Research Organization) as a Project Director with an emphasis on oncology molecules and worked for 5 years with Hoffmann La-Roche in numerous capacities. Dr. Szakacs also taught, and conducted research at the University of Saskatchewan, where he received his Ph.D. in Pharmacology.

Simon Pedder, the companys President and CEO stated, We are committed to building a world-class team with exceptional competencies in clinical, regulatory and business development. I am delighted with the progress we have made in assembling just such a team". Dr. Pedder joined the company in May, following several successful assignments at Hoffmann-La Roche Inc. where he was most recently the Vice President of Pharmaceutical Business, Oncology.

About Chelsea Therapeutics, Inc.
Chelsea Therapeutics is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea develops technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Specifically, Chelsea concentrates its efforts on acquiring and developing technologies for the treatment of rheumatoid arthritis (RA), psoriasis, cancer and other immunological disorders.

Our lead molecule, CH-1504 (formerly know as MobileTrex), is a unique antifolate that we believe may be clinically superior to Methotrexate, an agent commonly used to treat RA, psoriasis and certain cancers. Pre-clinical trials indicate that CH-1504 may have superior efficacy, less toxicity and increased tolerability.
   
For more information contact info@chelseatherapeutics.com
   
Or call: 704-341-1516
   
Website: www.chelseatherapeutics.com
###